IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts

Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1035-44. doi: 10.1152/ajpgi.00494.2001.

Abstract

Colonic subepithelial myofibroblasts (SEMFs) may play a role in the modulation of mucosal inflammatory responses. We investigated the effects of interleukin (IL)-17 on IL-6 and chemokine [IL-8 and monocyte chemoattractant protein (MCP)-1] secretion in colonic SEMFs. Cytokine expression was determined by ELISA and Northern blotting. Nuclear factor kappa B (NF-kappaB) DNA-binding activity was evaluated by electrophortetic gel mobility shift assay (EMSA). The activation of mitogen-activated protein kinase (MAPK) was assessed by immunoblotting. IL-6, IL-8, and MCP-1 secretions were rapidly induced by IL-17. IL-17 induced NF-kappaB activation within 45 min after stimulation. A blockade of NF-kappaB activation markedly reduced these responses. MAPK inhibitors (SB-203580, PD-98059, and U-0126) significantly reduced the IL-17-induced IL-6 and chemokine secretion. The combination of either IL-17 + IL-1beta or IL-17 + tumor necrosis factor (TNF)-alpha enhanced cytokine secretion; in particular, the effects of IL-17 + TNF-alpha on IL-6 secretion were much stronger than the other responses. This was dependent on the enhancement of IL-6 mRNA stability. In conclusion, human SEMFs secreted IL-6, IL-8, and MCP-1 in response to IL-17. These responses might play an important role in the pathogenesis of gut inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Cells, Cultured
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Colon / cytology*
  • Enzyme Inhibitors / pharmacology
  • Fibroblasts / drug effects
  • Fibroblasts / immunology*
  • Fibroblasts / metabolism
  • Gene Expression / drug effects
  • Gene Expression / immunology
  • Humans
  • Inflammatory Bowel Diseases / immunology
  • Interleukin-1 / pharmacology
  • Interleukin-17 / pharmacology*
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism
  • Interleukin-8 / genetics
  • Interleukin-8 / metabolism
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / metabolism*
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism*
  • Proline / analogs & derivatives*
  • Proline / pharmacology
  • Protein Synthesis Inhibitors / pharmacology
  • RNA, Messenger / analysis
  • RNA, Messenger / metabolism
  • Thiocarbamates / pharmacology
  • Tosylphenylalanyl Chloromethyl Ketone / pharmacology
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Antineoplastic Agents
  • Chemokine CCL2
  • Enzyme Inhibitors
  • Interleukin-1
  • Interleukin-17
  • Interleukin-6
  • Interleukin-8
  • NF-kappa B
  • Protein Synthesis Inhibitors
  • RNA, Messenger
  • Thiocarbamates
  • Tumor Necrosis Factor-alpha
  • prolinedithiocarbamate
  • Tosylphenylalanyl Chloromethyl Ketone
  • Proline
  • Mitogen-Activated Protein Kinases